Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Beckman Coulter Diagnostics has received FDA 510(k) clearance for the Access 25(OH) Vitamin D Total assay. The assay is available for use on the company’s Access 2 and UniCel DxI series of immunoassay systems and provides excellent stability and convenient storage through packaging designed to prevent light-induced reagent degradation.
February—Roche Diagnostics has signed a definitive purchase agreement with AvanSci Bio for all products associated with the high-performance microdissection of slide-mounted tissue sections. The system consists of instrumentation, software, and consumables used by researchers and clinicians to extract specific areas of tissue with high precision and purity for subsequent molecular analysis including real-time PCR, microarrays, and sequencing.
February 2014—Alpha-Tec Systems’ Stain Quality Control Slides are designed to ensure the quality, accuracy, and reliability of stain reagents and staining procedures. The slides provide a known positive and negative control that the laboratory can use to limit the batch-to-batch differences in staining procedures and standardize diagnostic criteria.
January 2015—eBioscience, an Affymetrix business that offers a broad spectrum of immunology and oncology research reagents, and the Binding Site Group have entered into a multiyear distribution agreement.
January 2015—Quest Diagnostics now offers BRCAvantage Plus, the company’s first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA and BRCA genes.
January 2015—Enzo Life Sciences introduced an LH ELISA Kit for sensitive and rapid detection of luteinizing hormone.
January 2015—Biocept launched its lung cancer liquid biopsy testing, performed at its CLIA-certified, CAP-accredited laboratory. The blood-based biomarker testing for non-small cell lung cancer, along with the previously commercialized breast cancer offering, provides options for health care professionals and researchers for when a tumor biopsy is not available or is unsafe to perform or when additional information is desired.
January 2015—Claritas Genomics and NextCode Health announced a strategic partnership bringing together pediatric medicine and sequence analysis. Claritas Genomics, affiliated with Boston Children’s Hospital, is a CLIA-certified clinical laboratory serving the DNA-based diagnostic testing needs of children’s hospitals.
January 2015—Seegene is introducing the first three comprehensive Allplex assays using its next-generation qPCR technology, called MuDT. The assay launch menu includes a 26-target Respiratory Full Panel, a 26-target Gastrointestinal Infection Full Panel, and a 27-target Sexually Transmitted Infection Full Panel.
January 2015—Results from three studies presented at the 37th Annual San Antonio Breast Cancer Symposium on BioTheranostics’ Breast Cancer Index molecular test provided additional evidence of its predictive and prognostic abilities.
